Cancer Science-2013
OMICS Group Conferences
Accelerating Scientific Discovery
3rd World Congress on
Cancer Science & Therapy
October 21-23, 2013 DoubleTree by Hilton Hotel San Francisco Airport, USA

Newcompouds of ruthenium present potencial of treatment for cancer

Elisangela de Paula Silveira Lacerda
Universidade Federal de Goias, Brazil

Abstract

The limitations of cisplatin-based chemotherapy, including high toxicity, undesirable side effects, and drug resistance, have motivated extensive investigations into alternative metal-based cancer therapies. A range of Ruthenium's complexes has been synthesized and tested for antitumor properties. Ruthenium (II) complexes are increasingly attracting the interest of researchers due to their promising pharmacological properties and selectivity to cells tumor. The aim of this work was to study of the cytotoxicactivity, arrest cell cycle and the mechanism of apoptosis of many cell lines induced byruthenium compound Ru*in vitro*in many line cell tumor. The present study determined the effects of the compoundsin S180, A549, K562 and Erlich tumor cellslines in the citotoxicity, cell cycle distribution, induction apoptosis, mitochondrial membrane potential, caspase activity and mRNA expression of genes bax and caspase-3 and 8. The MTT assay revealed that the IC_{50} for the compound after 48 h of incubation with S180 cells was approximately 31.15 µM. Cell cycle analysis revealed that some compounds of Ru(II)were capable of change cell cycle distribution since the percentage of cells in the G1 phases increased. In addition, treatment with these compounds induced apoptotic cell death in S180, A549, K562 and Erlich tumor cells, demonstrated by the increased numbers of Annexin V-positive cells, activation caspase 3 and 9 and marked decrease in mitochondrial membrane potential. Real time RT-PCR analysis revealed that Ru increased significant mRNA expression of many biomarket like bax and caspase-3. In summary,the new compounds of Ruthenium displayed a significant effect cytotoxic through cell cycle arrest and apoptotic induction in many tumor line cells, which suggests these compounds might have therapeutic potential anticancer.

Biography

Elisangela de Paula Silveira Lacerda has completed his Ph.D at the age of 25 years from Federal University of Uberlnadia in Genetics and Biochemistry. She is the professor of the Federal University of Goiás and the president of the Society of Genetics Region Goiás. She has published more than 20 papers in reputed journals and serving as an editorial board member of repute.